Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (715) 715
Patent (83) 83
Publication (55) 55
Book Chapter (6) 6
Reference (2) 2
Book Review (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (298) 298
hematology (175) 175
middle aged (173) 173
female (172) 172
male (171) 171
index medicus (166) 166
adult (162) 162
aged (159) 159
prognosis (111) 111
aged, 80 and over (108) 108
oncology (102) 102
leukemia, myeloid, acute - genetics (90) 90
chemistry (85) 85
acute myeloid-leukemia (84) 84
microbiology (84) 84
beer (83) 83
biochemistry (83) 83
compositions or test papers therefor (83) 83
condition-responsive control in microbiological orenzymological processes (83) 83
enzymology (83) 83
measuring or testing processes involving enzymes, nucleicacids or microorganisms (83) 83
metallurgy (83) 83
mutation or genetic engineering (83) 83
processes of preparing such compositions (83) 83
spirits (83) 83
vinegar (83) 83
wine (83) 83
mutation (77) 77
physics (71) 71
adolescent (69) 69
acute myelogenous leukemia (64) 64
minimal residual disease (62) 62
investigating or analysing materials by determining theirchemical or physical properties (61) 61
measuring (61) 61
testing (61) 61
genetics & heredity (59) 59
cytogenetics (54) 54
karyotyping (53) 53
leukemia (53) 53
young adult (50) 50
chromosome aberrations (47) 47
acute myeloid leukemia (42) 42
in situ hybridization, fluorescence (42) 42
acute disease (41) 41
aml (41) 41
cancer (36) 36
hemic and lymphatic diseases (35) 35
leukemia, myeloid - genetics (35) 35
analysis (34) 34
translocation, genetic (34) 34
acute lymphoblastic-leukemia (33) 33
polymerase chain reaction (33) 33
mutations (32) 32
abridged index medicus (31) 31
cohort studies (31) 31
genetic aspects (31) 31
nuclear proteins - genetics (31) 31
immunophenotyping (30) 30
internal tandem duplication (30) 30
leukemia, myeloid, acute - diagnosis (30) 30
diagnosis (28) 28
fms-like tyrosine kinase 3 - genetics (28) 28
leukemia, myeloid, acute - pathology (28) 28
myelodysplastic syndromes - genetics (28) 28
survival analysis (28) 28
acute promyelocytic leukemia (27) 27
classification (27) 27
myelodysplastic syndrome (27) 27
gene (26) 26
gene expression (25) 25
leukemia, myeloid, acute - mortality (25) 25
oncogene proteins, fusion - genetics (25) 25
recurrence (25) 25
dna-binding proteins - genetics (24) 24
gene expression profiling (24) 24
myeloproliferative disorders - genetics (24) 24
biomarkers, tumor - genetics (23) 23
hematology, oncology and palliative medicine (23) 23
expression (22) 22
mutation - genetics (22) 22
reverse transcriptase polymerase chain reaction (22) 22
risk factors (22) 22
animals (21) 21
disease-free survival (21) 21
follow-up studies (21) 21
myelodysplastic syndromes (21) 21
research (21) 21
normal karyotype (20) 20
survival rate (20) 20
child (19) 19
chromosome banding (19) 19
dna mutational analysis (19) 19
genetic research (19) 19
prognostic-significance (19) 19
core binding factor alpha 2 subunit - genetics (18) 18
flow cytometry (18) 18
janus kinase 2 - genetics (18) 18
neoplasm proteins - genetics (18) 18
abnormalities (17) 17
genes (17) 17
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Minimal residual disease monitoring: a new era for childhood ALL
by Schnittger, Susanne
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 362 - 364
Hematology, Oncology and Palliative Medicine | ONCOLOGY | QUANTIFICATION | ACUTE LYMPHOBLASTIC-LEUKEMIA | PRIMERS | UKALL 2003 | RISK | RANDOMIZED CONTROLLED-TRIAL | PCR | CHILDREN | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Neoplasm, Residual - drug therapy | Neoplasm Recurrence, Local - drug therapy | Female | Male
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text BRAF Mutations in Hairy-Cell Leukemia
by Tiacci, Enrico and Trifonov, Vladimir and Schiavoni, Gianluca and Holmes, Antony and Kern, Wolfgang and Martelli, Maria Paola and Pucciarini, Alessandra and Bigerna, Barbara and Pacini, Roberta and Wells, Victoria A and Sportoletti, Paolo and Pettirossi, Valentina and Mannucci, Roberta and Elliott, Oliver and Liso, Arcangelo and Ambrosetti, Achille and Pulsoni, Alessandro and Forconi, Francesco and Trentin, Livio and Semenzato, Gianpietro and Inghirami, Giorgio and Capponi, Monia and Di Raimondo, Francesco and Patti, Caterina and Arcaini, Luca and Musto, Pellegrino and Pileri, Stefano and Haferlach, Claudia and Haferlach, Torsten and Schnittger, Susanne and Pizzolo, Giovanni and Foà, Robin and Farinelli, Laurent and Pasqualucci, Laura and Rabadan, Raul and Falini, Brunangelo
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 24, pp. 2305 - 2315
In this study, investigators identified activating mutations in BRAF (specifically V600E, which is also present in some melanomas and thyroid cancers) in all... 
MEDICINE, GENERAL & INTERNAL | CYCLIN D1 | CONSTITUTIVE ACTIVATION | ACUTE LYMPHOBLASTIC-LEUKEMIA | KINASE | THYROID-CARCINOMA | GENE-EXPRESSION | B-RAF | MELANOMA-CELLS | CANCER | GENOME | Humans | Middle Aged | Leukemia, Hairy Cell - genetics | Male | MAP Kinase Kinase Kinases - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | Lymphoma, B-Cell - genetics | Sequence Analysis, DNA | Leukemia, Hairy Cell - metabolism | Proto-Oncogene Proteins B-raf - genetics | Lymphoma, B-Cell - pathology | Adult | Female | Aged | Mutation | Leukemia, Hairy Cell - pathology | Care and treatment | Genetic aspects | Research | Diagnosis | Gene mutations | Leukemia, Hairy cell | Spleen | Flow cytometry | Hematology | Hairy cells | Leukemia | Extracellular signal-regulated kinase | MAP kinase | Genomes | Kinases | Medical diagnosis | Patients | Studies | Lymphocytes B | Protein kinase | Genetic analysis | Peripheral blood | Bone marrow | Lymphomas | Deoxyribonucleic acid--DNA | Tumors | B-cell lymphoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1
by Alexander Kohlmann and Vera Grossmann and Hans-Ulrich Klein and Sonja Schindela and Tamara Weiss and Beray Kazak and Frank Dicker and Susanne Schnittger and Martin Dugas and Wolfgang Kern and Claudia Haferlach and Torsten Haferlach
Journal of Clinical Oncology, ISSN 0732-183X, 08/2010, Volume 28, Issue 24, pp. 3858 - 3865
Purpose Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy that is characterized by features of both a myeloproliferative neoplasm and... 
MYELOFIBROSIS | ACTIVATING MUTATION | POLYCYTHEMIA-VERA | PROGNOSTIC-FACTORS | ONCOLOGY | ACQUIRED UNIPARENTAL DISOMY | MYELOPROLIFERATIVE NEOPLASMS | MYELOID MALIGNANCIES | ESSENTIAL THROMBOCYTHEMIA | MYELODYSPLASTIC SYNDROME | RISK-ASSESSMENT | Proto-Oncogene Proteins c-cbl - genetics | Predictive Value of Tests | ras Proteins - genetics | Prognosis | Humans | Leukemia, Myelomonocytic, Chronic - genetics | Middle Aged | Kaplan-Meier Estimate | Male | Proto-Oncogene Proteins - genetics | DNA-Binding Proteins - genetics | Adult | Female | Aged | Mutation | Genes, ras | Core Binding Factor Alpha 2 Subunit - genetics | Sequence Analysis, DNA - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
by Raphaël Itzykson and Olivier Kosmider and Aline Renneville and Véronique Gelsi-Boyer and Manja Meggendorfer and Margot Morabito and Céline Berthon and Lionel Adès and Pierre Fenaux and Odile Beyne-Rauzy and Norbert Vey and Thorsten Braun and Torsten Haferlach and François Dreyfus and Nicholas C.P. Cross and Claude Preudhomme and Olivier A. Bernard and Michaela Fontenay and William Vainchenker and Susanne Schnittger and Daniel Birnbaum and Nathalie Droin and Eric Solary
Journal of Clinical Oncology, ISSN 0732-183X, 07/2013, Volume 31, Issue 19, pp. 2428 - 2436
Purpose Several prognostic scoring systems have been proposed for chronic myelomonocytic leukemia (CMML), a disease in which some gene mutationsincluding... 
TET2 GENE | ONCOLOGY | POOR-PROGNOSIS | HEMATOPOIETIC STEM-CELLS | MYELOPROLIFERATIVE NEOPLASMS | ACUTE MYELOID-LEUKEMIA | RISK MYELODYSPLASTIC SYNDROMES | MODEL | FREQUENT ALTERATIONS | ASXL1 MUTATIONS | MOLECULAR MUTATIONS | Leukemia, Myelomonocytic, Chronic - diagnosis | Predictive Value of Tests | Prognosis | Humans | Leukemia, Myelomonocytic, Chronic - genetics | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Protein Splicing - genetics | Gene Expression Profiling | Adult | Female | Neoplasm Proteins - genetics | Risk Assessment | Leukemia, Myelomonocytic, Chronic - mortality | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Repressor Proteins - genetics | Genotype | Signal Transduction - genetics | Phenotype | Analysis of Variance | Epigenesis, Genetic - genetics | Aged | Mutation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
by Rüdiger Hehlmann and Martin C. Müller and Michael Lauseker and Benjamin Hanfstein and Alice Fabarius and Annette Schreiber and Ulrike Proetel and Nadine Pletsch and Markus Pfirrmann and Claudia Haferlach and Susanne Schnittger and Hermann Einsele and Jolanta Dengler and Christiane Falge and Lothar Kanz and Andreas Neubauer and Michael Kneba and Frank Stegelmann and Michael Pfreundschuh and Cornelius F. Waller and Karsten Spiekermann and Gabriela M. Baerlocher and Gerhard Ehninger and Dominik Heim and Hermann Heimpel and Christoph Nerl and Stefan W. Krause and Dieter K. Hossfeld and Hans-Jochem Kolb and Joerg Hasford and Susanne Saußele and Andreas Hochhaus
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Prognostic relevance of FLT3-TKD mutations in AML: The combination matters an analysis of 3082 patients
by Bacher, Ulrike and Haferlach, Claudia and Kern, Wolfgang and Haferlach, Torsten and Schnittger, Susanne
Blood, ISSN 0006-4971, 03/2008, Volume 111, Issue 5, pp. 2527 - 2537
We characterized the mutational status of the FLT3 tyrosine kinase domain (FLT3-TLD) in 3082 patients with newly diagnosed AML. FLT3-TKD mutations were... 
INTERNAL TANDEM DUPLICATION | STUDY-GROUP ULM | KINASE DOMAIN MUTATIONS | ACUTE MYELOGENOUS LEUKEMIA | ACTIVATING POINT MUTATIONS | NORMAL CYTOGENETICS | ACUTE MYELOID-LEUKEMIA | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | RECEPTOR TYROSINE KINASE | ACUTE PROMYELOCYTIC LEUKEMIA | Protein Structure, Tertiary | Recurrence | Prognosis | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Survival Rate | Genetic Markers | Mutation - genetics | fms-Like Tyrosine Kinase 3 - chemistry | Leukemia, Myeloid, Acute - mortality | fms-Like Tyrosine Kinase 3 - genetics | Thermodynamics | Leukemia, Myeloid, Acute - diagnosis | DNA Mutational Analysis | Karyotyping | Adolescent | Aged, 80 and over | Adult | Aged | Neoplasm Proteins - genetics | Leukemia, Myeloid, Acute - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
by Piazza, Rocco and Valletta, Simona and Winkelmann, Nils and Redaelli, Sara and Spinelli, Roberta and Pirola, Alessandra and Antolini, Laura and Mologni, Luca and Donadoni, Carla and Papaemmanuil, Elli and Schnittger, Susanne and Kim, Dong-Wook and Boultwood, Jacqueline and Rossi, Fabio and Gaipa, Giuseppe and De Martini, Greta P and Di Celle, Paola Francia and Jang, Hyun Gyung and Fantin, Valeria and Bignell, Graham R and Magistroni, Vera and Haferlach, Torsten and Pogliani, Enrico Maria and Campbell, Peter J and Chase, Andrew J and Tapper, William J and Cross, Nicholas C.P and Gambacorti-Passerini, Carlo
Nature Genetics, ISSN 1061-4036, 01/2013, Volume 45, Issue 1, pp. 18 - 24
Atypical chronic myeloid leukemia (aCML) shares clinical and laboratory features with CML, but it lacks the BCR-ABL1 fusion. We performed exome sequencing of... 
DIFFERENTIAL EXPRESSION | PROTEIN | FUSION | RNA-SEQ | GENETICS & HEREDITY | MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS | TUMOR-SUPPRESSOR | SELF-RENEWAL | DISORDERS | SCHINZEL-GIEDION SYNDROME | GENOME | Amino Acid Sequence | Prognosis | Histone Chaperones - genetics | Humans | Histone Chaperones - metabolism | Molecular Sequence Data | Nuclear Proteins - metabolism | Transcription Factors - genetics | Sequence Analysis, DNA | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - mortality | Amino Acid Motifs | Exome | Transcription Factors - metabolism | Carrier Proteins - genetics | Carrier Proteins - metabolism | Protein Phosphatase 2 - metabolism | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - genetics | Protein Binding | Protein Interaction Domains and Motifs | Mutation | Nuclear Proteins - genetics | Amino Acid Substitution | Gene mutations | Genetic aspects | Chronic myeloid leukemia | Research | Health aspects | Oncogenes | Cancer | Proteins | Pathogenesis | Genetic testing | Data bases | Deoxyribonucleic acid--DNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status
by Schnittger, Susanne and Haferlach, Claudia and Ulke, Madlen and Alpermann, Tamara and Kern, Wolfgang and Haferlach, Torsten
Blood, ISSN 0006-4971, 12/2010, Volume 116, Issue 25, pp. 5486 - 5496
Mutations in the IDH1 gene at position R132 coding for the enzyme cytosolic isocitrate dehydrogenase are known in glioma and have recently been detected also... 
FAVORABLE PROGNOSIS | UNSELECTED PATIENTS | ACUTE MYELOGENOUS LEUKEMIA | NORMAL CYTOGENETICS | NUCLEOPHOSMIN NPM1 | ISOCITRATE-DEHYDROGENASE 1 | ACUTE MYELOID-LEUKEMIA | CEBPA MUTATIONS | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | PARTIAL TANDEM DUPLICATION | Prognosis | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Risk Factors | Genotype | Immunophenotyping | Isocitrate Dehydrogenase - genetics | Male | Survival Rate | Mutation - genetics | Young Adult | Karyotyping | Adolescent | Polymerase Chain Reaction | Aged, 80 and over | Adult | Female | Aged | DNA, Neoplasm - genetics | Nuclear Proteins - genetics | Leukemia, Myeloid, Acute - classification | Leukemia, Myeloid, Acute - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Distinctive microRNA Signature of Acute Myeloid Leukemia Bearing Cytoplasmic Mutated Nucleophosmin
by Ramiro Garzon and Michela Garofalo and Maria Paola Martelli and Roger Briesewitz and Lisheng Wang and Cecilia Fernandez-Cymering and Stefano Volinia and Chang-Gong Liu and Susanne Schnittger and Torsten Haferlach and Arcangelo Liso and Daniela Diverio and Marco Mancini and Giovanna Meloni and Robin Foa and Massimo F. Martelli and Cristina Mecucci and Carlo M. Croce and Brunangelo Falini
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 3/2008, Volume 105, Issue 10, pp. 3945 - 3950
Acute myeloid leukemia (AML) carrying NPM1 mutations and cytoplasmic nucleophosmin (NPMc+ AML) accounts for about one-third of adult AML and shows distinct... 
Up regulation | MicroRNA | Myeloid leukemia | Leukemia | Cell lines | Oligonucleotides | Signatures | Gene expression | Genetic mutation | Blood | HOX | NPM1 | FLT3-ITD | INTERNAL TANDEM DUPLICATION | MULTIDISCIPLINARY SCIENCES | ACUTE MYELOGENOUS LEUKEMIA | NPM1 MUTATIONS | CEBPA MUTATIONS | NORMAL KARYOTYPE | FAVORABLE PROGNOSTIC-SIGNIFICANCE | GENE-EXPRESSION PROFILE | DIFFERENTIATION | CELL | NPMC(+) AML | Antigens, CD34 - metabolism | Homeodomain Proteins - metabolism | Humans | Mutant Proteins - genetics | Cytoplasm - metabolism | Up-Regulation - genetics | Gene Expression Profiling | Gene Expression Regulation, Leukemic | Mutation - genetics | Neoplasm Proteins - metabolism | fms-Like Tyrosine Kinase 3 - metabolism | Transcription Factors - metabolism | Cell Line, Tumor | MicroRNAs - genetics | Myeloid Ecotropic Viral Integration Site 1 Protein | Nuclear Proteins - genetics | Cluster Analysis | Leukemia, Myeloid, Acute - genetics | RNA | Gene mutations | Homeobox genes | Influence | Genetic aspects | Properties | Cytoplasm | Biological Sciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: Correlation to cytomorphology, cytogenetics, and clinical data
by Kern, Wolfgang and Haferlach, Claudia and Schnittger, Susanne and Haferlach, Torsten
Cancer, ISSN 0008-543X, 10/2010, Volume 116, Issue 19, pp. 4549 - 4563
BACKGROUND: The diagnosis and classification of myelodysplastic syndromes (MDS) is based on cytomorphology (CM) and cytogenetics (CG). Multiparameter flow... 
Cytogenetics | Flow cytometry | Myelodysplasia | Cytomorphology | AML | WORKING CONFERENCE | BONE-MARROW | IN-SITU HYBRIDIZATION | CLASSIFICATION | COOPERATIVE GROUP | ACUTE MYELOID-LEUKEMIA | cytogenetics | myelodysplasia | ONCOLOGY | COMPLEX ABERRANT KARYOTYPE | flow cytometry | MYELOMONOCYTIC LEUKEMIA | SCORING SYSTEM | cytomorphology | Erythrocytes - immunology | Flow Cytometry - methods | Humans | Monocytes - immunology | Antigens, CD - analysis | Myelodysplastic Syndromes - diagnosis | Cytodiagnosis | Chromosome Aberrations | Myelodysplastic Syndromes - mortality | Myelodysplastic Syndromes - genetics | Myeloid Cells - pathology | Myelodysplastic Syndromes - pathology | Granulocytes - immunology | Myelodysplastic Syndromes - immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text The molecular profile of adult T‐cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T‐ALL
by Grossmann, Vera and Haferlach, Claudia and Weissmann, Sandra and Roller, Andreas and Schindela, Sonja and Poetzinger, Franziska and Stadler, Kathrin and Bellos, Frauke and Kern, Wolfgang and Haferlach, Torsten and Schnittger, Susanne and Kohlmann, Alexander
Genes, Chromosomes and Cancer, ISSN 1045-2257, 04/2013, Volume 52, Issue 4, pp. 410 - 422
T‐cell acute lymphoblastic leukemia (T‐ALL) is an aggressive and heterogeneous disease. The diagnosis is predominantly based on immunophenotyping. In addition... 
GENETIC-BASIS | ONCOLOGY | RELEVANCE | NOTCH1 MUTATIONS | GENETICS & HEREDITY | CHRONIC LYMPHOCYTIC-LEUKEMIA | ACUTE MYELOID-LEUKEMIA | PHF6 MUTATIONS | CTCF | DIFFERENTIATION | EXPRESSION | FBXW7 MUTATIONS | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Prognosis | Humans | Middle Aged | Male | DNA (Cytosine-5-)-Methyltransferases - metabolism | Young Adult | DNA Methylation | Aged, 80 and over | Adult | Female | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - metabolism | Genetic Predisposition to Disease - genetics | Chromosome Banding | Core Binding Factor Alpha 2 Subunit - metabolism | Gene Frequency | Immunophenotyping | In Situ Hybridization, Fluorescence | Receptor, Notch1 - metabolism | DNA (Cytosine-5-)-Methyltransferases - genetics | Comparative Genomic Hybridization | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Survival Analysis | Aged | High-Throughput Nucleotide Sequencing | Mutation | Receptor, Notch1 - genetics | Core Binding Factor Alpha 2 Subunit - genetics | Methyltransferases | Analysis | Genes | Cytogenetics | Genetic aspects | Acute lymphocytic leukemia | T cells | Methylation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
by Daniela Cilloni and Aline Renneville and Fabienne Hermitte and Robert K. Hills and Sarah Daly and Jelena V. Jovanovic and Enrico Gottardi and Milena Fava and Susanne Schnittger and Tamara Weiss and Barbara Izzo and Josep Nomdedeu and Adrian van der Heijden and Bert A. van der Reijden and Joop H. Jansen and Vincent H.J. van der Velden and Hans Ommen and Claude Preudhomme and Giuseppe Saglio and David Grimwade
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 31, pp. 5195 - 5201
PURPOSE: Risk stratification in acute myeloid leukemia (AML) is currently based on pretreatment characteristics. It remains to be established whether relapse... 
PROGNOSTIC IMPACT | NORMAL KARYOTYPE | AML 10 TRIAL | ONCOLOGY | CANCER PROGRAM | BONE-MARROW | RQ-PCR | MUTATIONS | STEM-CELL TRANSPLANTATION | EXPRESSION | TUMOR GENE WT1 | Prognosis | Gene Expression - drug effects | Humans | Middle Aged | Risk Factors | Child, Preschool | Neoplasm, Residual - genetics | Young Adult | Leukemia, Myeloid, Acute - diagnosis | Genes, Wilms Tumor | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | DNA Mutational Analysis | Reverse Transcriptase Polymerase Chain Reaction - methods | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Aged | Biomarkers, Tumor - genetics | Child | Leukemia, Myeloid, Acute - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome
by Volkert, Sarah and Kohlmann, Alexander and Schnittger, Susanne and Kern, Wolfgang and Haferlach, Torsten and Haferlach, Claudia
Genes, Chromosomes and Cancer, ISSN 1045-2257, 05/2014, Volume 53, Issue 5, pp. 402 - 410
We analyzed 1,200 patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) harboring a 5q deletion in order to clarify whether the type of... 
ONCOLOGY | ABNORMALITIES | GENETICS & HEREDITY | THERAPY-RELATED MYELODYSPLASIA | DEL(5Q) | DELETIONS | MDS | Chromosome Deletion | Translocation, Genetic | Prognosis | Genetic Association Studies | Humans | Middle Aged | Abnormal Karyotype | Tumor Suppressor Protein p53 - genetics | Myelodysplastic Syndromes - diagnosis | Leukemia, Myeloid, Acute - diagnosis | Early Growth Response Protein 1 - genetics | Aged, 80 and over | Adult | Aged | Myelodysplastic Syndromes - genetics | Mutation | Chromosomes, Human, Pair 5 - genetics | Clonal Evolution | Leukemia, Myeloid, Acute - genetics | Genetic research | Genetic aspects | Tumor proteins | Chromosomes | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text BCR‐ABL1‐positive and JAK2 V617F‐positive clones in 23 patients with both aberrations reveal biologic and clinical importance
by Martin‐Cabrera, Pedro and Haferlach, Claudia and Kern, Wolfgang and Schnittger, Susanne and Haferlach, Torsten
British Journal of Haematology, ISSN 0007-1048, 01/2017, Volume 176, Issue 1, pp. 135 - 139
BCR‐ABL1 | JAK2 V617F | myeloproliferative neoplasm | chronic myeloid leukaemia | BCR-ABL1 | TRANSLOCATION | JAK2(V617F) MUTATION | MYELOPROLIFERATIVE DISORDERS | BCR-ABL | LEUKEMIA | HEMATOLOGY | Leukemia | Patients | Janus kinase 2 | Aberration
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group
by Thomas Büchner and Wolfgang E. Berdel and Claudia Haferlach and Torsten Haferlach and Susanne Schnittger and Carsten Müller-Tidow and Jan Braess and Karsten Spiekermann and Joachim Kienast and Peter Staib and Andreas Grüneisen and Wolfgang Kern and Albrecht Reichle and Georg Maschmeyer and Carlo Aul and Eva Lengfelder and Maria-Cristina Sauerland and Achim Heinecke and Bernhard Wörmann and Wolfgang Hiddemann
Journal of Clinical Oncology, ISSN 0732-183X, 01/2009, Volume 27, Issue 1, pp. 61 - 69
Purpose The purpose of the study was to assess the contribution of age and disease variables to the outcome of untreated patients with acute myeloid leukemia... 
GENE-MUTATIONS | ADULT PATIENTS | PROLONGED MAINTENANCE | COLONY-STIMULATING FACTOR | SOUTHWEST-ONCOLOGY-GROUP | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | COUNCIL AML11 TRIAL | RANDOMIZED-TRIAL | MYELODYSPLASTIC SYNDROME | INDEPENDENT PROGNOSTIC RELEVANCE | Multivariate Analysis | Prognosis | Age Factors | Humans | Middle Aged | Male | Dose-Response Relationship, Drug | Leukemia, Myeloid, Acute - mortality | fms-Like Tyrosine Kinase 3 - genetics | Adolescent | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Mutation | Nuclear Proteins - genetics | Leukemia, Myeloid, Acute - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights